The world's first human trial of whether a drug can essentially make a person's cells younger sets up a reality check for one of the longevity field's most promising theories.
Why it matters: The early-stage clinical trial will signal whether "cellular reprogramming" can be performed safely in humans, a prerequisite for any future claim that a treatment can slow or even reverse biological aging.
Uber has signed a long-term lease for a 50,000-square-foot Houston depot, with plans to house 40 EV chargers and 15 maintenance bays, laying the groundwork for a robotaxi launch in the Bayou City in 2027.
Why it matters: Behind every robotaxi fleet is a lot of physical infrastructure — and Uber's race to secure it is taking place in cities well before its driverless cabs ever hit the streets.
